Metabolic dysfunction-associated steatotic liver disease and gastroesophageal reflux disease: a mendelian randomization study in European and East Asian populations

被引:0
|
作者
Su, Chen'guang [1 ]
Liao, Zheng [1 ]
Li, Hewen [2 ]
Pei, Yinxuan [1 ]
Wang, Zixiang [1 ]
Li, Jian [1 ]
Liu, Jinlong [1 ,3 ]
机构
[1] Chengde Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Chengde, Hebei, Peoples R China
[2] Chengde Med Univ, Dept Minimally Invas Spine Surg, Affiliated Hosp, Chengde, Hebei, Peoples R China
[3] Hebei Key Lab Panvasc Dis, Chengde, Hebei, Peoples R China
关键词
metabolic dysfunction-associated steatotic liver disease; gastroesophageal reflux disease; mendelian randomization; causal effect; genome-wide association studies; ALANINE AMINOTRANSFERASE; RISK-FACTORS; ESOPHAGITIS; PREVALENCE; OBESITY; INSTRUMENTS; SYMPTOMS; BIAS;
D O I
10.3389/fgene.2024.1428334
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Numerous observational studies have shown a potential association between metabolic dysfunction-associated steatotic liver disease (MASLD) and gastroesophageal reflux disease (GERD). However, causality is unclear. This study utilized genome-wide association study (GWAS) genetic data to explore the causal relationship between MASLD and GERD in European and East Asian populations. Methods This study utilized a bidirectional, two-sample Mendelian randomization (MR) approach. All disease data were obtained from the GWAS database, and single nucleotide polymorphisms strongly associated with exposure were selected as instrumental variables. The inverse variance weighted (IVW) method is primarily utilized to evaluate the causal relationship between exposure and outcome. Finally, sensitivity analyses were performed to ensure the robustness of the results. Results The IVW estimates indicated that non-alcoholic fatty liver disease (NAFLD) (odds ratio (OR) = 1.054, 95% confidence interval (CI), 0.966-1.150, p = 0.236) and percent liver fat (OR = 0.977, 95% CI, 0.937-1.018, p = 0.258) in European population were not linked to a higher risk of GERD. However, GERD in European population was associated with an increased risk of NAFLD (OR = 1.485, 95% CI, 1.274-1.729, p < 0.001) and percent liver fat (OR = 1.244, 95% CI, 1.171-1.321, p < 0.001). In addition, the IVW analysis in East Asian population showed that alanine aminotransferase (ALT) was associated with an increased risk of GERD (OR = 2.305, 95% CI, 1.241-4.281, p = 0.008), whereas aspartate aminotransferase (AST) had no causal effects on GERD risk (OR = 0.973, 95% CI, 0.541-1.749, p = 0.926). Furthermore, the associations between GERD and ALT (OR = 1.007, 95% CI, 0.998-1.015, p = 0.123) or AST (OR = 1.004, 95% CI, 0.997-1.012, p = 0.246) were not significant. After removing outliers, a significant correlation between GERD and ALT was observed (OR = 1.009, 95% CI, 1.001-1.016, p = 0.020). Conclusion There was reverse causality between MASLD and GERD in European population, while there was bidirectional causality between a proxie for MASLD (ALT) and GERD in East Asian population. This study can provide novel insights into cross-ethnic genetic research on MASLD and GERD.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [22] Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Kashihara, Takanori
    Fujmoto, Shota
    Kawaguchi, Tomoyuki
    Yokoyama, Reiko
    Kagemoto, Kaizo
    Tanaka, Hironori
    Kida, Yoshifumi
    Tomonari, Tetsu
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [23] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [24] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [25] A European Survey to Identify Challenges in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Castera, Laurent
    Alazawi, William
    Bugianesi, Elisabetta
    Caussy, Cyrielle
    Federici, Massimo
    Romero-Gomez, Manuel
    Schattenberg, Joern M.
    Basuroy, Ron
    Prasad, Preethy
    Estulin, Dmitry
    Lazarus, Jeffrey V.
    LIVER INTERNATIONAL, 2025, 45 (02)
  • [26] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [27] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [28] Causal association of gastroesophageal reflux disease on irritable bowel syndrome: a two-sample Mendelian randomization study
    Wu, Huihuan
    Li, Jingwei
    Li, FeiFei
    Lun, Weijian
    FRONTIERS IN GENETICS, 2024, 15
  • [29] Depression Promotes Gastroesophageal Reflux Disease: New Evidence Based on Mendelian Randomization
    Chen, Gui
    Xie, Junyang
    Ye, Jinfeng
    Kuang, Xiaoxuan
    Liao, Wenjing
    Song, Lijuan
    Zhang, Xiaowen
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2023, 34 (05) : 457 - +
  • [30] Gastroesophageal reflux disease and the risk of respiratory diseases: a Mendelian randomization study
    Dong, Rui
    Zhang, Qianqian
    Peng, Hongxing
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)